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Abstract
All over the world ischemic heart disease remains as the leading cause of death, 
followed by stroke. Ischemic heart disease, also called coronary artery disease has 
a broad spectrum of clinical manifestations from the acute coronary syndromes 
which include, unstable angina pectoris and acute myocardial infarction with and 
without elevation of the ST segment and chronic coronary disease. In patients with 
diabetes mellitus the cardiovascular complications mainly ischemic heart disease, 
are the main cause of morbidity and mortality. However, in population-based 
studies, the risk of heart failure in patients with diabetes mellitus is significantly 
increased following adjustment for well-established heart failure risk factors such 
as hypertension or ischemic heart disease. Ischemic heart failure angiographically 
diagnosed is associated with a shorter survival than non-ischemic heart failure. 
Coronary artery disease is independently associated with higher mortality.
Keywords: myocardial infarction, coronary artery disease, heart failure, Ischemic 
heart disease
1. Introduction
Ischemic disorders, such as peripheral vascular disease, stroke and myocardial 
infarction, are the most common causes death in the world. Cardiovascular diseases 
are the main cause of death globally, with an estimated 17.9 million deaths each 
year, representing 31% of all global deaths. Of these deaths, 85% are a consequence 
of myocardial infarction and stroke. Over 75% of cardiovascular disease deaths 
take place in low- and middle-income countries [1]. The main cause of myocardial 
infarction is coronary artery disease, and in turn the main cause of coronary artery 
disease is atherosclerosis. The rupture of atheroma plaque is the event that lead to 
the thrombus formation with the subsequent occlusion of the blood supply distal 
to the affected vessel segment. The magnitude of the tissue injury is directly related 
to the extent of the territory affected by the reduction in blood flow and the length 
of the ischemic period, which influences the levels at which intracellular pH and 
ATP are reduced. Follow-up of groups of patients with characteristics that favor 
the appearance of atherosclerosis over time, has allowed the identification of risk 
factors for cardiovascular disease, as well as the development of various predictive 
models, such as the Framingham score.
The main cause of ischemic heart disease is coronary artery disease caused by 
atherosclerosis. There are secondary causes of ischemia, these can cause ischemic 
heart disease and non-obstructive myocardial infarction of the coronary arteries 
(INOCA and MINOCA), these secondary causes are classified in coronary, myocar-
dial and non-cardiac causes.
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2. Atherosclerotic artery disease
The term atherosclerosis is rooted in the Greek word αθερα (“athero”, which 
means crushed food in the form of a mass) for the aspect of the necrotic core 
area and the word σκλεροζ (“scleros” which means hard) for hardening or indu-
ration, referring to the fibrous layer of the luminal edge. Atherosclerosis is an 
inflammatory process that begins from childhood and develops over the years, 
is asymptomatic most of the time; is distinguished by retention, oxidation and 
modification of lipids in the form of fatty streaks on the walls of the arteries that 
later evolve to fibrous plaques causing wall thickening in the affected artery, 
decreasing its internal diameter over time. Rupture of this plaque cause throm-
bosis and occlusion of the blood supply to the myocardial tissue irrigated by the 
affected artery [2].
The main cause of Ischemic heart disease is atherosclerosis. Coronary athero-
sclerotic disease can be classified into three types: obstructive coronary artery 
disease, non-obstructive coronary artery disease, and microvascular coronary 
artery disease. In addition to arteriosclerosis and thrombosis of the coronary arter-
ies, other causes of acute myocardial infarction are extremely rare. Cases have been 
described of infarction caused by embolization within the coronary arteries from 
clot fragments from elsewhere, or septic embolization due to endocarditis of the 
aortic valve.
3. Definition of myocardial infarction
The introduction of more sensitive cardiac biomarkers has led the American 
College of Cardiology (ACC) and the European Society of Cardiology (ESC) to col-
laborate for the redefinition of myocardial infarction using a clinical and biochemi-
cal approach. These societies reported that myocardial injury detected by abnormal 
biomarkers in the context of acute myocardial ischemia should be labeled as in the 
fourth universal definition of myocardial infarction. In other words, myocardial 
infarction is defined as the presence of acute myocardial damage detected by the 
elevation of cardiac biomarkers in the context of evidence of acute myocardial 
ischemia [3].
Myocardial infarction can be defined from the point of view of pathological 
anatomy as myocardial cell death due to prolonged ischemia. The first ultra-
structural changes are diminished cellular glycogen, sarcolemmal disruption, 
and relaxed myofibrils and they are seen as early as 10–15 min after the onset of 
ischemia. Mitochondrial abnormalities are observed as early as 10 minutes after 
coronary occlusion by electron microscopy [4, 5].
Cardiac troponins are regulatory proteins that mediate interaction between 
actin and myiosin, there are two types of cardiuacx troponins; troponin T (cTnT) 
and troponin I (cTnI), The cTnI has not been identified outside the myocardium. 
Cardiac troponin T is expressed to a small extent in skeletal muscle; however, the 
current cTnT assay does not identify skeletal troponins Myocardial injury is defined 
by detection of an elevated cardiac troponin (cTn) value above the 99th percentile 
URL. The injury is considered acute if there is a rise and/or fall of cTn values. The 
biomarkers of choice for the evaluation of myocardial damage are cTnI and cTnT; 
the use of high-sensitivity cTn (hs-cTn) is recommended in routine clinical practice 
[6]. Other biomarkers, such as the MB fraction of creatine kinase (CK-MB), are less 
sensitive and specific (Table 1).
Of patients with acute coronary syndrome, 1 to 14% do not have identifiable 




Patients with myocardial infarction and non-obstructive coronary arteries 
(MINOCA), represent a conundrum given the many potential underlying etiolo-
gies. MINOCA is defined as angiographic stenosis <50% and myocardial infarction 
Possible causes of MINOCA can be subdivided into coronary, myocardial, and 
non-cardiac disorders (Figure 1).
Classification of myocardial infarction
Myocardial 
infarction type I




Caused by mismatch between oxygen supply and demand, the pathophysiological 
mechanism lead to ischaemic myocardial injury.
Myocardial 
infarction type 3
Patients that manifest with a typical presentation of myocardial ischemia/
infarction, including presumed new ischaemic ECG changes or ventricular 
fibrillation, and die before it is possible to obtain blood for cardiac biomarker 
determination; or the patient may succumb soon after the onset of symptoms 




Associated with percutaneous coronary intervention.
Type 4b.
Stent/scaffold thrombosis associated with percutaneous coronary intervention.
Type 4c.
Restenosis associated with percutaneous coronary intervention.
Myocardial 
infarction type 5
Associated with coronary artery bypass grafting.
Table 1. 
Classification of myocardial infarction according the fourth universal definition of myocardial infarction.
Figure 1. 
Etiologies of MINOCA.
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MINOCA is found in up to 14% of patients presenting with an acute coronary 
syndrome. Many terms have been used to describe patients with acute myocardial 
infarction or acute coronary syndrome with normal or near-normal coronary arter-
ies, such as MINOCA, MINCA (MI with normal coronary arteries) and INOCA 
(ischemia and no obstructive coronary artery disease) The most common patholo-
gies associated with an acute coronary syndromes are plaque rupture, erosion and 
calcified nodules which are present in 44%, 31% and 8% respectively.
Plaque formation starts with the formation of fatty streaks and intimal thicken-
ing, leading to fibrous cap atheroma and eventually to fibrous cap thinning. This so-
called thin-cap fibroatheroma can rupture. In plaque erosion, there is an abundance 
of smooth muscle cells without an extensive necrotic core, hemorrhage or calcifica-
tion. It differs from plaque rupture, as there is an absence of fibrous cap disruption. 
Identification of vulnerable plaques on coronary angiography can be challenging. 
Intravascular coronary imaging and computed tomography angiography could play 
an important role in finding these plaques in the future.
An elevated troponin beyond the 99th percentile of the upper reference level is 
a hallmark of myocardial injury in the same way that it is for myocardial infarction. 
However, myocardial injury is attributable to non-ischemic mechanisms of myocyte 
injury and in this way these entities differ conceptually from ischemic heart disease.
The diagnosis of MINOCA requires the fulfillment of the following criteria:
1. Acute myocardial infarction. Detection of a rise or fall of cTn value with at 
least one value above the 99th percentile upper reference limit and corrobora-
tive clinical evidence of infarction evidenced by at least one of the following 
criteria:
• Symptoms consistent with myocardial ischemia.
• New electrocardiographic changes consistent with ischemia.
• Development of pathological Q waves.
• Evidence of a new loss of viable myocardium or a new regional wall motion 
abnormality with a pattern consistent with an ischemic cause on imaging 
studies.
• Evidence by angiography or autopsy of a coronary thrombus.
2. Evidence on angiography of non-obstructive coronary arteries, defined as the 
absence of obstructive disease (no coronary artery stenosis ≥50% in any major 
epicardial vessel). This includes the following cases:
• Normal coronary arteries with no angiographic stenosis.
• Angiographic stenosis with <30% stenosis and mild luminal irregularities.
• Moderate coronary atherosclerotic lesions defined as stenosis >30% 
but <50%.
3. Absence of an alternate clinical diagnosis to explain the presentation
• Alternate diagnoses include but are not limited to non-ischemic causes such 




Among MINOCA patients coronary plaque disruption is common. The terms 
plaque rupture, plaque erosion, and calcific nodules are included in the term plaque 
disruption. Plaque rupture is an event that can trigger the formation of a thrombus 
that leads to myocardial infarction due to superimposed coronary spasm, distal 
embolization, or in some cases, transient complete thrombosis that resolves with 
spontaneous thrombolysis.
Coronary artery spasm is an intense vasoconstriction with more than 90% 
lumen occlusion of an epicardial coronary artery that compromises myocardial 
blood flow. Hyperresponsiveness to toxins or drugs of vascular smooth muscle cells 
can lead to vasospasm of the coronary arteries, or it can occur spontaneously due to 
disorders in coronary vasomotor tone.
In 30–50% of patients with non-obstructive coronary artery disease docu-
mented by invasive coronary angiography and presenting with chest pain or 
discomfort, coronary microvascular dysfunction can be detected. Microvascular 
dysfunction is seen more frequently in women and patients with classic cardiovas-
cular risk factors. Microvascular dysfunction can be a cause of ischemia, but it can 
also be a consequence of myocardial injury.
Coronary embolism or thrombosis can cause MINOCA if it involves the micro-
circulation or if there is partial lysis of the epicardial coronary thrombus it can 
result in coronary disease that is not obstructive by coronary angiography. This can 
occur with or without a hypercoagulable state. Disorders with increased coagu-
lability that cause coronary thrombosis can be classified as inherited or acquired. 
Among these disorders is the antiphospholipid syndrome, which is a heterogeneous 
disorder characterized by the presence of autoantibodies against protein-phospho-
lipid complexes. Hereditary thrombophilia is prevalent in the general population, 
with a variable prevalence depending on race/ethnicity. Acquired hypercoagulable 
states include thrombotic thrombocytopenic purpura, antiphospholipid syndrome, 
heparin-induced thrombocytopenia, and myeloproliferative neoplasms.
Spontaneous coronary artery dissection is a relatively rare non atherosclerotic 
mechanism of myocardial infarction. The separation of the medial and adventitial 
vascular walls associated with intramural hematoma protrusion into the lumen 
cause obstruction to coronary blood flow. The primary source of the dissection is 
still controversial and the exact mechanism is not entirely known.
4. Myocardial ischemia-reperfusion injury
Occlusion of a coronary artery causes sudden cessation of regional perfusion, 
rapidly leading to the cessation of aerobic metabolism, creatine phosphate deple-
tion, and the onset of anaerobic glycolysis; this continues to build up of lactate 
and catabolites and progressively reduces ATP levels. If ischemia continues, tissue 
acidosis develops and cellular ion exchange is impaired, the function of the cell 
membrane is impaired, triggering the onset of myocyte death. Irreversible myocar-
dial damage begins in the subendocardium 20 minutes after coronary occlusion and 
extends as a wave front towards the subepicardial layers; after one hour of coronary 
occlusion, the dependent subendocardium and part of the myocardium are irrevers-
ibly damaged; transmural extension is completed with 4–6 h of ischemia.
Reperfusion entails a replenishment of substrates, mainly oxygen, which will 
intervene in the oxidation of fatty acids at the mitochondrial level. Complete 
restoration of contractile function is achieved when adenosine triphosphate (ATP) 
levels normalize and excess adenosine diphosphate (ADP, platelet aggregation 
agonist) disappears. There are other factors, such as changes in calcium flux due 
to membrane alterations or alterations in the metabolism of free fatty acids, which 
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are responsible for the prolonged abnormality of contraction after ischemia [7–9]. 
Endothelial damage activates the coagulation cascade with platelet and red cell 
aggregation that contribute to microvascular dysfunction [10]; the inflammatory 
response with complement activation also influences myocardial perfusion dys-
function [11] and other changes such as glycogen and ATP depletion, mitochondrial 
edema and nuclear chromatin clumping correlate with worsening myocardial 
function after ischemia (stunned myocardium) [12–14].
Reperfusion of the affected vessel during an acute myocardial infarction is 
crucial to save the ischemic myocardium, but it also causes a metabolic injury that 
can be reversible, as in the case of myocardial stunning [15–17], but it can also be 
irreversible and manifest as microvascular dysfunction and an increase in the size 
of the infarcted myocardium. This phenomenon is known as myocardial ischemia–
reperfusion injury.
Several molecular mechanisms have been shown to be involved in the etiology 
of myocardial ischemia–reperfusion injury including defects in calcium handling, 
mitochondrial damage, reactive oxygen species production, and inflammation.
5. Apoptosis
Both calcium overload and oxidative stress can induce on the mitochondrial 
permeability transition pores abrupt opening. This abrupt opening of these pores 
causes uncoupling of oxidative phosphorylation and mitochondrial swelling, 
thereby inducing apoptosis and cell necrosis [18–19]. The apoptosis process is 
energy-dependent. It gets activated during ischemia, but it is not effected until 
the oxygen supply is reinitiated during reperfusion. Caspase activation is a pri-
mordial event in apoptosis. Caspase inhibition during early reperfusion has been 
demonstrated to protect the myocardium against reperfusion injury in a murine 
model [20].
6. Defects in calcium handling
For the maintenance of the excitation-contraction coupling in cardiomyocytes, 
calcium homeostasis plays an essential role. During the cardiac action potential, 
extracellular calcium enters the cell through L-type calcium channels, the ryano-
dine receptor 2 (RyR2) is activated by intracellular calcium leading to increased 
release of calcium from the sarcoplasmic reticulum. Intracellular calcium present 
at a certain level cause myocardial contraction, by binding to the myofilament of 
the contractile protein troponin C. On the one hand, the sarcoplasmic reticulum 
calcium-ATPase (SERCA) recaptures intracellular calcium, bringing it back to the 
sarcoplasmic reticulum. On the other hand, the sodium-calcium exchanger (NCX) 
expels calcium from the cells and the dissociation of calcium from the myofilament 
protein leads to cardiomyocite relaxation. SERCA, NCX, RyR2, and mitochondria 
regulate the calcium levels in myocardial cells, and also participate in calcium over-
load during ischemic injury. The common clinical characteristics of the myocardial 
induced reperfusion injury are myocardial reperfusion arrhythmias, stunning, 
intramyocardial hemorrhage, microvascular obstruction, and enlargement of the 
myocardial infarction [21–24].
After a period of hypoxia and ischemia, myocardial cells have an increase in 
anaerobic metabolism, this leads to the intracellular aggregation of hydrogen ions, 
which causes a low intracellular pH and an increase in intracellular sodium through 




excretion and calcium uptake by the sodium calcium exchanger ultimately resulting 
in calcium overload.
Calcium plays a fundamental role in the coupling of cardiac excitation-contrac-
tion. Thus, the calcium overload will increase the reperfusion injury and the size 
of the infarcted myocardium. Excess intracellular calcium will enter the mitochon-
dria and this excess mitochondrial calcium inhibits ATP production, exacerbates 
energy metabolism disorders, and ultimately leads to apoptosis of myocardial cells. 
Mitochondrial damage is known to be a marker of irreversible damage in cardio-
myocytes [25–26].
Disturbances of calcium homeostasis play a key role in the development of 
reperfusion arrhythmias, including idioventricular rhythm, ventricular tachycar-
dia, and ventricular fibrillation [27]. Inhibition of intracellular calcium overload 
improves recovery of cardiac function [28].
7. Autophagy and mitophagy
The phenomenon called “mitophagy” consists of the activation of cellular 
autophagy and degradation of damaged mitochondria by lysosomes and is generally 
beneficial because they reduce the reperfusion injury [29].
Ischemia is known to stimulate autophagy. This occurs through a mechanism 
dependent on adenosine monophosphate activated protein kinase (AMPK), 
while ischemia–reperfusion causes left ventricular dysfunction and autophagic 
myocardial cell death through a Beclin-1 dependent mechanism, but independent 
of AMPK. The increase in autophagosomes containing damaged mitochondria is 
associated with the latter event [30, 31].
8. Inflammation
A sequence of cellular events leading to collagen-based scar formation leads 
to healing of the infarcted myocardium. This is a consequence of the fact that the 
heart of adult mammals has little regenerative capacity. Three overlapping phases 
describe the repair of the infarcted myocardium: the inflammatory, the prolifera-
tive and the maturation phases. Inflammation exerts a key role in cardiovascular 
diseases, as extensively reported in the literature. Inflammatory responses exert 
a different effect in the acute and chronic phase. Activation of inflammatory 
responses acutely contributes to the healing process including release of cytokines 
and infiltration of inflammatory cells into the myocardium, while prolonged activa-
tion of inflammation triggers pro-apoptotic pathways [32–34].
Reperfusion of the infarcted area of the myocardium triggers a complex inflam-
matory reaction accompanied by infiltration of inflammatory leukocytes into 
the compromised myocardial region and the release of cytokines. This release of 
cytokines and the inflammatory response after myocardial infarction are an integral 
part of the healing process and contribute to the remodeling of cardiac tissue, 
however, excessive inflammatory responses are detrimental to the integrity of the 
extracellular matrix and to cell survival. This occurs through enhanced activation of 
pro-apoptotic signaling pathways, with a subsequent poor clinical outcome [35–37].
Tissue injury generates endogenous signals that activate the innate immune 
system; these molecules belong to a large group of mediators that warn the body of 
injury and are known as damage-associated molecular patterns (DAMPs). A group 
of structurally diverse endogenous signals are released after tissue necrosis occurs, 
promoting cell activation of innate immune systems through binding to recognition 
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pattern receptors, these are known by the term alarmins. High mobility group B1 
(HMGB1) is the best characterized alarmin and is a key initiator of inflammatory 
injury following myocardial ischemia through actions that might involve the recep-
tor for advanced glycation end products (RAGE) and toll-like receptors (TLRs). 
The fact that both harmful and beneficial effects of HMGB1 have been reported 
in the infarcted myocardium is not surprising given the critical role of alarmin-
mediated signaling in inflammation and repair of myocardial tissue. The identifica-
tion of danger signals by innate immune cells occurs through participation of TLRs, 
a family of transmembrane receptors that activate subsequent pro-inflammatory 
cascades. Studies of loss of genetic function indicate that TLR2 and TLR4, both 
located on the cell surface, are important mediators of the post-infarction inflam-
matory reaction.
A molecular program that leads to the recruitment of inflammatory cells in the 
healing infarct is activated by alarmin-mediated signaling. The pro-inflammatory 
chemokines induced in the infarcted heart generate chemotactic gradients that lead 
to the recruitment of subpopulations of leukocytes through interactions with the 
corresponding chemokine receptors. Upregulation of pro-inflammatory cytokines 
(such as IL-1β, members of the IL-6 family and tumor necrosis factor [TNF]) 
induce molecule synthesis, endothelial cell adhesion, and activate leukocyte integ-
rins, mediating strong adhesive interactions that ultimately lead to extravasation of 
inflammatory cells into the infarct.
In the infarcted myocardium the expression of the two main chemokine sub 
families (C-C y C-X-C) mediate the inflammatory leukocyte recruitment, The 
neutrophyl recruitment is mediated by the chemokines CX-C with amminoacid 
secuence Glu-Leu-Arg which are quickly induced by the infarcted myocardium.
9. Oxidative stress
Oxidative stress can be produced from enzymatic sources and non-enzymatic 
sources. Common enzymatic sources include the xanthine oxidase system, mito-
chondrial electron transport chain, NADPH oxidase system, and uncoupled nitric 
oxide synthase (NOS) system. Non-enzymatic sources are a minor source of oxida-
tive stress, and include hemoglobin and myoglobin. The xanthine oxidase system, 
NADPH oxidase system, and mitochondrial electron transport chain are broadly 
implicated in oxidative stress in several organs, including the heart, lung, brain, 
muscle, intestine, liver, pancreas, stomach, and kidney. NOS is a major oxidative 
stress factor in the liver, heart, and aortic endothelial cells [38–40].
The onset of acute myocardial ischemia during an acute myocardial infarction 
induces cell damage and the death of different constituents of the myocardium. 
This, in turn, initiates an acute pro-inflammatory response through the concerted 
action of several processes including the production of reactive oxygen species, 
the activation of the complement cascade, and the damage-associated molecular 
patterns that serve as ligands for pattern recognition receptors (PRRs) a family 
of cytosolic nucleotide-binding oligomerization domain receptors (NLRP3, also 
known as Nod-like receptors) and toll like receptors This result in the release of a 
variety of pro-inflammatory mediators such as cytokines and chemokines, which 
induce the recruitment of inflammatory cells into the infarcted zone, and augment 
the pro-inflammatory response following acute myocardial infarction.
Infiltrating leukocytes can induce cardiomyocyte death by targeting the viable 






Heart failure is a complex syndrome responsible for high rates of death and 
hospitalization among the general population worldwide. One of the most frequent 
causes of HF is ischemic heart disease.
Heart failure is a clinical syndrome characterized by typical symptoms (breath-
lessness, ankle swelling, and fatigue) that may be accompanied by signs (e.g. 
elevated jugular venous pressure, pulmonary crackles, and peripheral oedema) 
caused by a structural and/or functional cardiac abnormality, resulting in a reduced 
cardiac output and/or elevated intracardiac pressures at rest or during stress. 
Demonstration of an underlying cardiac cause is central to the diagnosis. This 
is usually a myocardial abnormality causing systolic and/or diastolic ventricular 
dysfunction (Figure 2).
The two main types of heart failure are the acute and chronic forms. In 
chronic heart failure which is the most common type, symptoms appear slowly 
over time and gradually worsen with various underlying mechanisms such as 
mechanical stress, ischemia, infections, autoimmune diseases, and genetic 
diseases [41–45].
The regeneration process in ischemic heart disease after myocardial infarction 
begins with the infiltration of leukocytes. This is triggered by ischemia and the 
presence of necrotic cardiomyocytes to eliminate irreparably damaged or dead cells 
and allows repair of the infarcted area through the formation of scars to maintain 
cardiac integrity [46, 47].
A significant number of inflammatory cells, including monocytes/macrophages 
and neutrophils that infiltrate the infarct area, are considered to be an essential 
component of very early wound healing processes. It is through the polarization of 
macrophages towards a reparative phenotype that neutrophils orchestrate post-
infarction healing. The polarization of neutrophils is mediated by DAMPs and the 
neutrophils themselves can polarize towards different phenotypes, for example, 
neutrophils N1 and N2 in the infarct region [48–51]. The cellular immune response 
and the subsequent inflammatory response are considered a key factor in adverse 
left ventricular remodeling after an acute myocardial infarction. The New York 
Heart Association (NYHA) functional classification has been used to describe the 
Figure 2. 
Ischemic heart disease features in the etiology of heart failure.
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severity of symptoms and exercise intolerance in heart failure. Although there is a 
clear relationship between the severity of symptoms and survival, the severity of 
symptoms is poorly correlated with many measures of left ventricular function, 
and patients with mild symptoms may be at high risk of hospitalization and death 
(Figure 3) [52–54].
Estimation of prognosis for morbidity, disability and death helps patients, their 
families and clinicians decide on the appropriate type and timing of therapies (in 
particular, decisions about a rapid transition to advanced therapies) and assists with 
planning of health and social services and resources (Figure 3) [55].
Virtually any measurement that can be performed in a biological system is 
included in the definition of a biomarker, this term in the context of heart failure is 
limited to substances measured in the blood other than electrolytes and commonly 
used markers of kidney or liver function. The plasma concentration of natriuretic 
peptides (NPs) can be used as an initial diagnostic test, especially in the non-acute 
setting when echocardiography is not immediately available. Elevated NPs help 
establish an initial working diagnosis, identifying those who require further cardiac 
investigation; patients with values below the cut-point for the exclusion of impor-
tant cardiac dysfunction do not require echocardiography [55].
Figure 3. 
Diagnostic algorithm from the ESC guidelines for the diagnosis and treatment of acute and chronic heart 
failure for the diagnosis of heart failure of non-acute onset [55]. BNP = B-type natriuretic peptide; 
CAD = coronary artery disease; HF = heart failure; MI = myocardial infarction; NT-proBNP = N-terminal 




The fact that several drugs for HF have shown detrimental effects on long-term 
outcomes, despite showing beneficial effects on shorter-term surrogate markers, 
has led regulatory bodies and clinical practice guidelines to seek mortality/morbid-
ity data for approving/recommending therapeutic interventions for HF. However, 
it is now recognized that preventing HF hospitalization and improving functional 
capacity are important benefits to be considered if a mortality excess is ruled out.
After of myocardial infarction the presence of ischemic heart failure mortality is 
a frequent complication. Several factors, such as infarct size, recurrent myocardial 
ischemia, ventricular remodeling, mechanical complications, stunned myocardium, 
and hibernating myocardium influence the appearance of left ventricular systolic 
dysfunction with or without clinical heart failure [56–58].
In 30–40% patients, the etiology of heart failure is nonischemic, the ischemic 
etiology is a significant independent predictor of mortality in patients with heart 
failure [59]. In the VALIANT registry were included 5573 consecutive MI patients at 
84 hospitals in nine countries from 1999 to 2001. A multivariable logistic survival 
model was constructed using baseline variables to determine the adjusted mortality 
risk for those with in-hospital heart failure and/or left ventricular systolic disfunc-
tion. The presence of heart failure precedes 80.3% of all in-hospital deaths after 
myocardial infarction, and the survivors. Heart failure post high risk myocardial 
infarction occurs in a time-dependent fashion and is usually not directly related to 
re-infarction [60, 61].
11. Conclusions
Ischemic heart disease remains as the leading cause of death in the world. 
Coronary atherosclerosis and related ischemic heart failure is a leading cause of 
heart failure with reduced ejection fraction, the heart failure of ischemic ethiology 
is associated with a shorter survival and more complications than non-ischemic 
heart failure. The heart failure and systolic left ventricle dysfunction are present in 
more than the 80% of in-hospital deaths after myocardial infarction. Substantial 
improvements in the prevention and management of heart failure present formi-
dable challenges, but these challenges may be met because much of the necessary 
ground work has already been carried out.
It is important to highlight that for the clinician who faces the challenge of treat-
ing patients with ischemic heart disease, it is important to know its mechanisms 
and the therapies aimed at both the management of patients with acute myocardial 
infarction and heart failure. The goals of treatment in patients with HF are to 
improve their clinical status, functional capacity, quality of life, prevent hospital 
admission, and reduce mortality.
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